Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plitidepsin Safety in Hospitalized COVID-19
NCT04382066Phase 1Completed
- Sponsor
- PharmaMar
- Start
- May 2020
- Primary completion
- Nov 2020
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of plitidepsin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by PharmaMar. Primary endpoints: Frequency of Occurrence of Neutropenia >= Grade 3, Frequency of Occurrence of Thrombocytopenia >= Grade 3 and 12 more. Started May 2020; status: completed.
02
Drugs
plitidepsin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04382066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382066.